A Study of LY3209590 in Healthy Participants and Participants With Type 2 Diabetes
Completed · Phase 1 · NCT02942914
Conditions: Diabetes Mellitus, Type 2
At a glance
- Research payments reported, 2025
- $71,552
- U.S. investigators named
- 10
- Sites paid
- 10
- Planned or actual enrollment
- 80
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3209590 (drug), Placebo (drug), Insulin Glargine (drug)
- Dates
- Started 2016-12-20; completion 2017-10-18
- Results posted
- Not yet
This trial is conducted to evaluate the safety of a study drug given by injection under the skin to healthy participants and participants with type 2 diabetes. It will also investigate how the body processes the study drug and the effect of the study drug on blood sugar levels. Information about any side effects and tolerability will be documented. This study is approximately 30 days for each participant, not including screening. Screening is required within 28 days prior to the start of the study.
From ClinicalTrials.gov, last updated 2017-11-07. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $71,552 in research payments for this study in 2025 (10 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Aaron W. Karr, D.O. Family Medicine · Sheffield, AL
- Diana T. Widicus, MD Family Medicine · Rochester, IL
- Jonathan D. Condit, DO Family Medicine · Muncie, IN
- Cyrus V. Desouza, MD Endocrinology & Diabetes · Omaha, NE
- Suchet R. Patel, MD Family Medicine · Endwell, NY
- Lisa B. Connery, M.D. Family Medicine · Norman, OK
- Bryce Palchick, M.D. Family Medicine · Pittsburgh, PA
- Elizabeth A. Barranco, MD Internal Medicine · Ponce, PR
- Gerardo Bueso, MD Endocrinology & Diabetes · Houston, TX
- Chad Crystal, M.D. Emergency Medicine · Palestine, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Endocrine Associates $22,844
- Meridian Clinical Research LLC $14,450
- Alliance for Multispecialty Research Lls $6,837
- Syed Research Consultants LLC $5,250
- Preferred Primary Care Physicians Inc $5,000
- Unehealth $4,186
- Prairie Education and Research Coop $3,550
- Ponce School of Medicine $3,500
- American Health Network of in LLC $3,201
- Eastside Research Associates LLC $2,734
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.